| 摘要 |
FIELD: medicine, oncology. ^ SUBSTANCE: the present innovation deals with applying fulvestrant as a curative preparation of the third line in treating patients with resistant cancer of mammary gland after failed application of tamoxifen and aromatase inhibitor. The innovation shows positive therapeutic result in 41% cases. ^ EFFECT: higher sensitivity to fulvestrant. ^ 5 cl, 1 ex, 1 tbl
|
